



Rui Tato Marinho (MD, PhD)

Director Clínico/Medical Director Centro Hospitalar Universitário Lisboa Norte (Hospital Santa Maria/Hospital Pulido Valente)


Diretor National Program for Viral Hepatitis



Faculdade de Medicina da Universidade de Lisboa



Formation in Health
...agement (450 hours, 19





Me!



Several NGOs



5 kms







Hepatitis NANB going C?

THE LANCET, AUGUST 3, 1974

LONG-INCUBATION POST-TRANSFUSION HEPATITIS WITHOUT SEROLOGICAL EVIDENCE OF EXPOSURE TO HEPATITIS-B VIRUS

ALFRED M. PRINCE

GEORGE F. GRADY

CHARLES HAZZI



STEPHEN J. MILLIAN

BETSY BROTMAN

WILLIAM J. KUHN

RICHARD W. LEVINE

*Laboratory of Virology, New York Blood Center;
State Laboratory Institute, Massachusetts Department of
Public Health, Boston; Departments of Pathology and
Medicine, New York University School of Medicine; and
Virus Laboratory, New York City Department of Health*



Our findings imply that a substantial proportion of post-transfusion hepatitis cases is caused neither by HB virus nor hepatitis A agent, and suggest the existence of an additional virus(es), hepatitis type C.



1991 - Data in PWID!!

INFECÇÕES VÍRICAS EM TOXICODEPENDENTES DE DROGAS ENDOVENOSAS. Significado Clínico e Prognóstico



HELENA GLÓRIA, F. RAMALHO, R. MARINHO, MARÍLIA PEDRO, J. VELOSA, M. CARNEIRO MOURA

Unidade de Hepatologia e Centro de Gastreenterologia (INIC). Serviço de Imuno-Hemoterapia. Hospital de Santa Maria. Lisboa.

QUADRO 2— Prevalência global de marcadores para o VHB, VHD, VHC e HIV1


	N.º casos	N.º casos positivos	
		N.º	(%)
AgHBs	131	28	21.4
VHB	121	98	81
VHD	110	20	18.2
VHC	100	83	83
HIV1	120	1	0.8

QUADRO 1—Dados epidemiológicos em 135 toxicodependentes de drogas endovenosas

N.º	135
Homens	107
Mulheres	28
Índice H/M	3.8/1
Idade média (anos)	25±4
(variação)	(14-35)
Consumo médio de drogas ev (anos)	6.2±4
(variação)	(0.5-17)
Partilha de seringas (%)	82



This is Liver





HOSPITAL DE
SANTAMARIA
CENTRO HOSPITALAR LISBOA NORTE, EPE



Hospital
Pulido Valente



The European Board
of Gastroenterology
& Hepatology

EUROPEAN
BOARD
OF GASTROENTEROLOGY
AND HEPATOLOGY




FACULDADE DE
MEDICINA
LISBOA




Organograma CHLN 2016

Elaborado de acordo com alteração ao art. 38 do Regulamento Interno, de 29 jan. 2015



80% PWID



Lisbon



Plano Nacional para a Hepatite C

1989

1991

1997

2001

2005
FibroScan

2010

2014



U. CE. Hepatologia



~1-1,5%



96%

Res. Virol. 1997 Mar-Apr;148(2):143-5.

The threat to public health of hepatitis C.

Lavanchy D.

Author information

WHO, Division of Emerging and other Communicable Diseases Surveillance and Control, Geneva, Switzerland.



HCV 3% world



Almost Free for all, NHS Decriminalization

2000

1. Overall efficiency in all WHO member states

Overall efficiency

Rank	Uncertainty Interval	Member State	Index	Uncertainty Interval
1	1 - 5	France	0.994	0.982 - 1.000
2	1 - 5	Italy	0.991	0.978 - 1.000
3	1 - 6	San Marino	0.988	0.973 - 1.000
4	2 - 7	Andorra	0.982	0.966 - 0.997
5	3 - 7	Malta	0.978	0.965 - 0.993
6	2 - 11	Singapore	0.973	0.947 - 0.998
7	4 - 8	Spain	0.972	0.959 - 0.985
8	4 - 14	Oman	0.961	0.938 - 0.985
9	7 - 12	Austria	0.959	0.946 - 0.972
10	8 - 11	Japan	0.957	0.948 - 0.965
11	8 - 12	Norway	0.955	0.947 - 0.964
12	10 - 15	Portugal	0.945	0.931 - 0.958
13	10 - 16	Monaco	0.940	0.920 - 0.957
14	13 - 19	Greece	0.933	0.921 - 0.945
15	12 - 20	Iceland	0.932	0.917 - 0.948
16	14 - 21	Luxembourg	0.928	0.914 - 0.942
17	14 - 21	Netherlands	0.928	0.914 - 0.942
18	16 - 21	United Kingdom	0.925	0.913 - 0.937
19	14 - 22	Ireland	0.924	0.909 - 0.939
20	17 - 24	Switzerland	0.916	0.903 - 0.930



CASE STUDY




DRUG DECRIMINALISATION IN PORTUGAL: SETTING THE RECORD STRAIGHT

KEY POINTS

- Drug-related deaths fell after the reform of Portugal's drug policy, and have remained below the EU average since 2001
- The proportion of the prison population sentenced for drug offences has fallen from over 40% to 15%
- Rates of drug use have remained consistently below the EU average
- Portugal has gone from accounting for over 50% of yearly HIV diagnoses linked to injecting drug use in the EU to 1.7%

NEW HIV DIAGNOSES ATTRIBUTED TO INJECTING DRUG USE

Data: ECDC⁴⁰



1998 ... THE PROBLEMS ... TODAY

2%

IV Route

16%

Heroin users

0,33%

Population

3%

HIV new cases


33 200

Problematic users

63

Overdoses deaths

Number of deaths per million people, latest available data



Source: National Records of Scotland. Note: No data available for Greece



Top – Five Stars

1. National Health System, Free Health for All (1979), the 12th most efficient by WHO (2000)
2. Annual Meeting European Association Study Liver (EASL), Lisbon (1981)
3. Scientific Medical Societies (Portuguese Association for the Study of the Liver 1983, GEPCOI – Grupo Estudos de Coinfeção, 2006)
4. Hepatitis B and C treatment free for all (1987) – Interferon
5. Liver Units, outpatient Consultation for Hepatology (1989)
6. Very active civil society (NGOs, 1990)
Liga Portuguesa Contra SIDA, Abraço, Sol, Associação Positivo
7. Risk reduction (OST, NSP 1990)
8. Liver transplant (1992)
9. Safer Blood (1992)
10. Subspeciality in Hepatology by Portuguese Board Association (1995)
11. 33rd Annual Meeting EASL, Lisbon (1998)
12. National Strategy Against Drugs (1999)
13. Hepatitis B vaccine, birth dose at Hospital for all newborns (2000)
14. Drugs decriminalization (2000)
15. Elastography (Fibroscan) (2005)
16. Free medical treatment for hepatocelular carcinoma (2007)
Plus imagiology, surgery, liver transplant,
17. HCV clinical trials for DAA, with publications in NEJM (2013)
18. Hepatitis C treatment free for all (2015)
19. Microelimination in dialysis (2016)
20. Microelimination in prisons (2018)
21. National Priority Program for Viral Hepatitis (2018 autonomous in 2021)
22. Task-Force for severe acute hepatitis in children (2022)
23. Portugal as a founding member – United Nations Group of Friends for Viral Hepatitis (2022)
24. World Hepatitis Alliance/WHO in Lisbon, 9-11 April, Portugal, 2024



Point of Care



Going Local







GOVERNO DE
PORTUGAL

MINISTÉRIO DA SAÚDE

Ministry of Health



Portuguese Parliament



JORNAL DA SAÚDE PARLAMENTO
7ª edição
27 junho a 1 julho 2016
consulte o programa na ARQ



Mr. President





Hospital Going

To Prison

E. P. Lisboa

~1000 pop

1.9 km from Hospital



Going to Prisons



The Kit



Consumption Rooms




Homeless



report tallied the costs against the relief for the homeless (including free shelter, assistance programs, free heroin, and prevention services) and concluded that investing in a street sleeper offers the highest return on investment around. Every euro invested in fighting homelessness in the Netherlands enjoys returns in savings on social services, police costs.³⁵

“Relief is preferable and less expensive than the street,” the researchers concluded. Their calculations only looked at the savings for government, of course eliminating the problem of homelessness have payoffs for a city’s businesses and residents.

Relief for the homeless, in short, is a win-win-win-win policy.



Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Stefan Zeuzem, M.D., Ira M. Jacobson, M.D., Tolga Baykal, M.D.,
 ★ Rui T. Marinho, M.D., Ph.D., Fred Poordad, M.D., Marc Bourlière, M.D.,
 Mark S. Sulkowski, M.D., Heiner Wedemeyer, M.D., Edward Tam, M.D.,
 Paul Desmond, M.D., Donald M. Jensen, M.D., Adrian M. Di Bisceglie,
 Peter Varunok, M.D., Tarek Hassanein, M.D., Junyuan Xiong, M.D.,
 Tami Pilot-Matias, Ph.D., Barbara DaSilva-Tillmann, M.D., Lois Larse,
 Thomas Podsadecki, M.D., and Barry Bernstein, M.D.

ABSTRACT

BACKGROUND

In this phase 3 trial we evaluated the efficacy and safety of the combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also ABT-267), dasabuvir (also known as ABT-333), and ribavirin for the retreatment of HCV in patients who were previously treated with peginterferon–ribavirin.

This article was published on April 10, 2014, at NEJM.org.

DOI: 10.1056/NEJMoa1401561

Copyright © 2014 Massachusetts Medical Society.




Figure 1. Sustained Virologic Response in the Entire Active-Regimen Group and According to Hepatitis C Virus (HCV) Genotype.



Renascença



Sociedad Científica Española de Estudios sobre el Alcohol, el Alcoholismo y las otras Toxicomanías




Key Ideas

Once in Life



The Roadmap – Humanism and Dignity

- Political will, legislation
- National Organization for Drug Adiction (SICAD; DICAD)
- No stigma, all are humans
- Restorative Justice
- The fantastic NGOs
- Drugs are public health (mental), not only criminal
- All together, total package
- Needle Syringe Programs (global kit)
- Opioid Agonist Maintenance Therapy
- Hospital on road and streets
- Etc, etc





**REPÚBLICA
PORTUGUESA**

SAÚDE




286 / 297

All Patients




Figure 6. Targets for reducing new cases of and deaths from chronic viral hepatitis B and C infection



VHB – 40.000
VHC – 30.000




NEW INFECTIONS
DEATHS



2020
Hepatitis C
Alter
Houghton
Rice
Cura
Salvaram muitas Vidas

Figure 6. Targets for reducing new cases of and deaths from chronic viral hepatitis B and C infection







HSM>EPL

Consultation, Blood, Fibroscan



National Health Plan

2021-2030

14.3 Diabetes mellitus

13.8 TM estômago

12.7 TM cólon

Cirrhosis

10.7 TM mama

10.6 TM tecido linfático e hematopoético

10.2 Outras doenças cardíacas

9.4 Acidentes de transporte

9.0 Pneumonia

8.0 Suicídios

7.0 VIH/sida

6.7 Doenças crónicas vias aéreas inferiores

6.5 TM pâncreas

5.8 TM lábio, cavidade bucal e faringe

Liver Cancer

Ordenação 2007-2009

Ordenação 2016-2018

TMP 75

% Variação

sculares

brônquios e pulmões

do coração

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

20

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

23

TM laringe, traqueia, brônquios e pulmões

Doenças isquémicas do coração

Doenças cérebro-vasculares

TM estômago

TM cólon

Outras doenças cardíacas

TM tecido linfático e hematopoético

TM mama

Diabetes mellitus

TM pâncreas

Suicídios

Pneumonia

TM lábio, cavidade bucal e faringe

Acidentes de transporte

Doenças crónicas vias aéreas inferiores

VIH/sida

29.1

24.7

20.3

10.7

10.5

10.2

9.7

9.2

7.9

7.8

7.2

6.2

6.2

5.6

2.9

4.3%

-6.8%

-38.5%

-15.7%

2.9%

-3.8%

-9.3%

-35.7%

21.5%

-2.5%

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liver

Cirrhosis

Liver Cancer

TMP 75 - Taxa de mortalidade padronizada pela idade (<75 anos) | TM - Tumor maligno

Principais causas de morte e percentagem de variação da taxa de mortalidade padronizada pela idade (<75anos) em Portugal, idade prematura, ambos os sexos, 2007-2009 e 2016-2018

Lisbon, near me

URBAN INTERVENTION PLAN OF CASAL VENTOSO



1998-2000 (N=558)



HIV



HCV



TP



PWID



No
Treatment
Before

Light

Light
Fumos mais leves
Menos nicotina
Menos tarso

Insu Light

CE

100% LATEX FREE

Chesfordfield
Cigarettes

Fumar reduz a fertilidade

O fumo do tabaco contém mais de

Winston

Insu Light

CE

De 500 mg de nicotina para 0,5 mg de nicotina

ADU 5141

Agente Anti-Pruriginoso

EMULSÃO

Associação de Apoio
(Gratuita)
800 206 688

ado.pt

SPMS

Associação Portuguesa de Esclerose Múltipla

68



Insu Light

Atenção
em seringueira
em seringueira
em seringueira

ATENÇÃO
em seringueira
em seringueira
em seringueira

1.000 ml





GAT

GRUPO DE ATIVISTAS
EM TRATAMENTOS

GAT - Grupo de Ativistas em Tratamentos
Avenida Paris, 4, 1º andar, 1000-228 Lisboa
Tel.: 351 10 96 78 26 / Email: geral@gatportugal.org
www.gatportugal.org | GATPortugal | @GATVIH

FINANCIADORES

AHF EURO E Lus Arsivivt LISBOA

